These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 18421187

  • 1. Efficacy of risedronate in Japanese male patients with primary osteoporosis.
    Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.
    Intern Med; 2008; 47(8):717-23. PubMed ID: 18421187
    [Abstract] [Full Text] [Related]

  • 2. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
    Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.
    J Bone Miner Metab; 2009; 27(2):168-74. PubMed ID: 19183836
    [Abstract] [Full Text] [Related]

  • 3. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
    Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, Morimoto T, Corners J, Nakao K.
    J Bone Miner Metab; 2006; 24(2):105-13. PubMed ID: 16502116
    [Abstract] [Full Text] [Related]

  • 4. Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
    Takakuwa M, Iwamoto J, Itabashi K.
    Clin Drug Investig; 2012 Feb 01; 32(2):121-9. PubMed ID: 22185631
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
    Dundar U, Kavuncu V, Ciftci IH, Evcik D, Solak O, Cakir T.
    J Bone Miner Metab; 2009 Feb 01; 27(4):464-70. PubMed ID: 19301089
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
    Park SY, Kang MI, Park HM, Rhee Y, Moon SH, Yoon HK, Koh JM, Chang JS, Kim IJ, Won YY, Park YS, Choi H, Shin CS, Yoon TR, Yun SC, Chung HY, IDEAL Trial Investigators.
    Arch Osteoporos; 2019 Dec 09; 15(1):3. PubMed ID: 31820121
    [Abstract] [Full Text] [Related]

  • 8. Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study.
    Takakuwa M, Iwamoto J, Konishi M, Zhou Q, Itabashi K.
    J Bone Miner Metab; 2011 Jan 09; 29(1):88-95. PubMed ID: 20533068
    [Abstract] [Full Text] [Related]

  • 9. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
    Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H.
    Osteoporos Int; 2003 May 09; 14(3):225-34. PubMed ID: 12730746
    [Abstract] [Full Text] [Related]

  • 10. Secondary osteoporosis in long-term bedridden patients with cerebral palsy.
    Iwasaki T, Takei K, Nakamura S, Hosoda N, Yokota Y, Ishii M.
    Pediatr Int; 2008 Jun 09; 50(3):269-75. PubMed ID: 18533934
    [Abstract] [Full Text] [Related]

  • 11. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr 09; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 12. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group.
    Osteoporos Int; 2002 Dec 09; 13(12):971-9. PubMed ID: 12459940
    [Abstract] [Full Text] [Related]

  • 13. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
    Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE, Fosamax Actonel Comparison Trial investigators.
    Curr Med Res Opin; 2004 Dec 09; 20(12):2031-41. PubMed ID: 15706659
    [Abstract] [Full Text] [Related]

  • 14. Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis.
    Atmaca A, Gedik O.
    Adv Ther; 2006 Dec 09; 23(6):842-53. PubMed ID: 17276952
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
    Kanaji A, Higashi M, Namisato M, Nishio M, Ando K, Yamada H.
    Lepr Rev; 2006 Jun 09; 77(2):147-53. PubMed ID: 16895071
    [Abstract] [Full Text] [Related]

  • 17. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K.
    Calcif Tissue Int; 2007 Aug 09; 81(2):73-80. PubMed ID: 17612779
    [Abstract] [Full Text] [Related]

  • 18. Fracture risk remains reduced one year after discontinuation of risedronate.
    Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A.
    Osteoporos Int; 2008 Mar 09; 19(3):365-72. PubMed ID: 17938986
    [Abstract] [Full Text] [Related]

  • 19. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP.
    Bone; 2014 Jan 09; 58():48-54. PubMed ID: 24141036
    [Abstract] [Full Text] [Related]

  • 20. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Weryha G, Marques-Neto JF, Gaines KA, Verbruggen N, Melton ME.
    Clin Drug Investig; 2006 Jan 09; 26(2):63-74. PubMed ID: 17163237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.